SPN-812

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 34/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Attention-Deficit/Hyperactivity Disorder

Conditions

Attention-Deficit/Hyperactivity Disorder

Trial Timeline

Jan 23, 2020 → Dec 14, 2022

NCT ID

NCT04143217

About SPN-812

SPN-812 is a phase 3 stage product being developed by Supernus Pharmaceuticals for Attention-Deficit/Hyperactivity Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04143217. Target conditions include Attention-Deficit/Hyperactivity Disorder.

What happened to similar drugs?

8 of 10 similar drugs in Attention-Deficit/Hyperactivity Disorder were approved

Approved (8) Terminated (0) Active (2)

✅atomoxetineEli LillyApproved

✅AtomoxetineEli LillyApproved

✅Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + PlaceboNovartisApproved

✅SPN-812Supernus PharmaceuticalsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06185985	Approved	Completed	Mar 25, 2024	Dec 11, 2024	Attention-Deficit/Hyperactivity Disorder
NCT04786990	Approved	Completed	Jul 27, 2021	Jul 26, 2023	Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT04143217	Phase 3	Completed	Jan 23, 2020	Dec 14, 2022	Attention-Deficit/Hyperactivity Disorder
NCT02736656	Phase 3	Active	Feb 2, 2016	Sep 1, 2026	Attention-Deficit/Hyperactivity Disorder

Competing Products

18 competing products in Attention-Deficit/Hyperactivity Disorder

See all competitors

Product	Company	Stage	Hype Score
atomoxetine	Eli Lilly	Approved	39
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Approved	43
ABT-089 + atomoxetine + placebo	AbbVie	Phase 2	35
ABT-089 + Placebo	AbbVie	Phase 2	35
ABT-089	AbbVie	Phase 2	35
ABT-089 + placebo	AbbVie	Phase 2	35
MK0249 + Concerta (methylphenidate) + Placebo	Merck	Phase 2	35
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + Placebo	Novartis	Approved	43
SPN-812	Supernus Pharmaceuticals	Approved	37
IR Viloxazine + Placebo	Supernus Pharmaceuticals	Phase 1/2	26
SPN-812	Supernus Pharmaceuticals	Approved	37
100mg SPN-812 + Placebo	Supernus Pharmaceuticals	Approved	44
Placebo + SPN-812	Supernus Pharmaceuticals	Phase 3	34
Placebo + 100mg SPN-812 + 200mg SPN-812 + 300mg SPN-812 + 400mg SPN-812	Supernus Pharmaceuticals	Phase 2	29
SPN-812	Supernus Pharmaceuticals	Phase 3	38
TD-9855 + TD-9855 + Placebo	Theravance Biopharma	Phase 2	29